Login to Your Account



Zealand Signs Helsinn to €140M Deal for GLP-2 Agonist in CID

By Jennifer Boggs


Tuesday, December 2, 2008

Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID). (BioWorld Today)

 

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription